Daily Cardiology Research Analysis
Analyzed 24 papers and selected 3 impactful papers.
Summary
Three studies advance cardiology across thrombosis biology, immune sequelae, and imaging-based prognosis. A large cohort revealed a U-shaped link between factor XI activity and mortality, with CAD status modifying risk, informing FXI inhibitor strategies. Nationwide data showed myocarditis markedly elevates subsequent autoimmune disease risk, while pre-PCI coronary CTA features (plaque length, calcified volume, PCAT-FAI) improved prediction of events despite complete revascularization.
Research Themes
- Personalized anticoagulation guided by thrombosis biology (Factor XI)
- Autoimmune sequelae after myocarditis and long-term surveillance
- Imaging biomarkers (CTA plaque metrics and PCAT-FAI) for post-PCI risk stratification
Selected Articles
1. Non-linear association of coagulation factor XI with mortality.
In a 3,170-patient cohort with 14.5-year median follow-up, factor XI activity showed a U-shaped association with all-cause mortality, with the lowest risk at 115.6% activity. In CAD patients, higher FXI activity was linearly linked to increased mortality, and NT-proBNP significantly modified these relationships, supporting context-specific FXI inhibitor strategies.
Impact: Identifies a non-linear and CAD-dependent relationship between FXI activity and mortality, informing the design and patient selection for FXI inhibitor trials. It bridges thrombosis biology and clinical outcomes over long-term follow-up.
Clinical Implications: FXI inhibition may not be universally beneficial; CAD status and cardiac stress (NT-proBNP) should inform dosing or candidacy. Extreme low or high FXI activity may carry risk, arguing for personalized targets and monitoring.
Key Findings
- U-shaped association between FXI activity and mortality overall (p=0.027), nadir risk at 115.6% activity
- In CAD, mortality risk increased linearly with higher FXI activity (p interaction < 0.0001)
- NT-proBNP significantly modified FXI–mortality associations, especially in CAD patients
Methodological Strengths
- Large, well-characterized cohort with median 14.5-year follow-up
- Advanced modeling with restricted cubic splines and interaction analyses
Limitations
- Observational design with potential residual confounding
- Single cohort limits generalizability; external validation not presented
Future Directions: Prospective studies should test FXI inhibitor efficacy across strata of CAD and NT-proBNP, and evaluate target ranges to avoid harm at low FXI activity.
BACKGROUND: Coagulation factor XI (FXI) influences both thrombotic risk and myocardial function, making its relationship with mortality crucial for guiding therapies, especially in coronary artery disease (CAD). METHODS: We analyzed data from 3,170 participants who underwent coronary angiography; 67% were diagnosed with CAD. Participants were followed for a median of 14.5 years. Mortality risk was assessed using Cox proportional hazards models with restricted cubic splines and Wald statistics. Models were adjusted for age, sex, BMI, and further cardiovascular risk factors. Interactions between FXI activity, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and CAD were explored. FINDINGS: A U-shaped association between FXI activity and mortality was observed (p = 0.027), with the lowest risk at an FXI activity of 115.6%. Among patients without CAD, this U-shaped relationship persisted. In contrast, patients with CAD demonstrated a linear relationship, where higher FXI activity correlated with increased mortality (p interaction < 0.0001). NT-proBNP levels significantly modified these associations, particularly in patients with CAD. CONCLUSIONS: These findings emphasize the dual role of FXI activity in hemostasis, which could have profound implications for pharmacological interventions. The variable effects of FXI activity based on underlying cardiovascular conditions suggest that a personalized approach to treatment is necessary. Consequently, future studies on FXI inhibitors should carefully examine these modulating factors to optimize therapeutic strategies. FUNDING: The LURIC study was supported by the Ludwigshafen Heart Centre and academic collaborators, including the universities of Freiburg, Ulm, and Düsseldorf and the Centre Nationale de Genotypage in France, through internal institutional resources.
2. Risk of developing autoimmune and immune mediated disease following a diagnosis of myocarditis - a Danish nationwide register-based cohort study.
In a nationwide cohort of 2,671 myocarditis patients matched to 13,355 controls, autoimmune or immune-mediated diseases were substantially more frequent, with 10-year cumulative incidence 7.2% versus 2.9%. Risk was highest within 180 days (adjusted HR 10.29) and remained elevated long term (HR 2.45), particularly in women, and was accompanied by higher 10-year all-cause mortality.
Impact: Provides definitive population-level evidence that myocarditis confers immediate and sustained risk of autoimmune comorbidity, highlighting a critical surveillance window and sex differences.
Clinical Implications: Implement structured autoimmune screening and multidisciplinary follow-up after myocarditis—especially within the first 6 months and in women—integrating rheumatologic evaluation and patient education.
Key Findings
- 10-year cumulative incidence of autoimmune/immune-mediated diseases: 7.2% (myocarditis) vs 2.9% (controls)
- Adjusted HR ≤180 days: 10.29 (95% CI 6.14–17.23); >180 days: 2.45 (95% CI 2.02–2.97)
- Higher incidence in women (10-year 10.7% vs 4.4% in female controls); 10-year all-cause mortality 26.7% vs 13.0%
Methodological Strengths
- Nationwide registry with large matched control cohort and long follow-up
- Time-stratified hazard estimation distinguishing acute and chronic risk phases
Limitations
- Registry-based diagnoses may introduce misclassification
- Limited clinical granularity (e.g., immunophenotyping, biomarkers) and residual confounding
Future Directions: Prospective studies integrating biomarkers and immune profiling to identify high-risk subsets and test prevention strategies during the early high-risk window.
INTRODUCTION: Myocarditis is a severe condition characterized by myocardial inflammation. It is currently unknown if patients with myocarditis are at higher risk of developing autoimmune or immune mediated disease compared to the general population. PURPOSE: To estimate short- and long-term risk of developing autoimmune or immune mediated disease in patients with a first-time diagnosis of myocarditis. METHODS: We conducted a nationwide register-based cohort study using Danish national administrative registers. Endpoints were incidence of a composite of 35 autoimmune and immune-mediated diseases and all-cause mortality. RESULTS: A total of 2671 patients with myocarditis between 2002 and 2020 in Denmark were matched on age and sex (1:5) with background population controls (n = 13,355). Median age was 46 years (Q1-Q3: 28-67), and 69.7 % were men. The 10-year cumulative incidence of autoimmune or immune-mediated disease was 7.2 % in the myocarditis cohort and 2.9 % in controls. The adjusted hazard ratio (HR) for autoimmune or immune-mediated disease ≤180 days of follow-up was 10.29 (95 % CI: 6.14-17.23) for patients with myocarditis versus controls, and 2.45 (95 % CI 2.02-2.97) >180 days (median follow-up time 9.4 years [Q1-Q3: 5.4-14.6]). Female patients with myocarditis had a 10-year cumulative incidence of autoimmune or immune-mediated disease of 10.7 %, compared to 4.4 % in controls. Corresponding figures for male patients with myocarditis were 5.6 % versus 2.2 % for male controls. All-cause mortality at 10 years was 26.7 % in the myocarditis group and 13.0 % in controls. CONCLUSIONS: Patients with myocarditis had a significantly higher incidence of autoimmune and immune-mediated disease.
3. Coronary CT Angiography Quantitative Features and Outcomes After Complete Revascularization in Acute Coronary Syndrome: A Post Hoc Analysis of a Prospective PCI Registry.
In 1,027 ACS patients with complete revascularization, pre-procedural CTA features—calcified plaque volume, plaque length, and PCAT-FAI—independently predicted POCE over 2.8 years. Incorporating these features improved prognostic discrimination beyond clinical models (AUC 0.71 to 0.76).
Impact: Demonstrates that CTA plaque burden/length and perivascular inflammation signatures forecast residual risk post-complete revascularization, enabling refined surveillance and potential anti-inflammatory strategies.
Clinical Implications: Integrating CTA quantitative metrics into post-PCI risk models can identify patients at residual risk despite angiographic completeness, guiding intensified medical therapy and follow-up.
Key Findings
- Among 1,027 ACS patients, 8.7% experienced POCE over a median 2.8 years
- Independent predictors of POCE: calcified plaque volume (HR 1.21; P=0.04), plaque length (HR 1.23; P=0.049), PCAT-FAI (HR 1.37; P<0.01)
- Adding CTA features improved model AUC from 0.71 to 0.76 (P<0.01); vessel-level results were consistent in target and non-target vessels
Methodological Strengths
- Large consecutive cohort with standardized pre-PCI CTA quantification
- Multilevel analysis (patient and vessel level) and incremental value testing
Limitations
- Retrospective analysis without external validation; potential selection bias
- PCAT-FAI measurement standardization and causal inference limitations
Future Directions: External validation and interventional studies testing anti-inflammatory or anti-atherosclerotic strategies in high PCAT-FAI and long/ calcified plaque phenotypes.
RATIONALE AND OBJECTIVES: To evaluate the association of coronary CT angiography (CTA)-derived quantitative characteristics and pericoronary adipose tissue (PCAT) attenuation with cardiovascular events following complete revascularization. MATERIALS AND METHODS: This retrospective cohort study (March 2020-March 2023) enrolled consecutive acute coronary syndrome (ACS) patients receiving complete revascularization. Pre-procedural CTA quantified plaque volume, composition, length, and PCAT attenuation. The primary endpoint was the patient-oriented composite endpoint (POCE: cardiac death, myocardial infarction, ischemia-driven revascularization). Vessel-oriented composite endpoint (VOCE) was assessed at the vessel level. Data entry and auditing were performed by formally trained research staff to ensure high data accuracy and minimize missing data. No imputation was used to infer missing values. RESULTS: Among 1027 patients (mean age, 60.5 years ± 10.0 [standard deviation]; 748 men), 89 (8.7%) experienced POCE over median 2.8-year follow-up. In the adjusted model, greater calcified plaque volume (hazard ratio [HR], 1.21; P = 0.04), longer plaque length (HR, 1.23; P = 0.049), and higher PCAT fat attenuation index (FAI) (HR, 1.37; P<0.01) predicted POCE. Per-vessel analysis yielded consistent findings, with plaque length, calcified volume, and PCAT-FAI significantly associated with VOCE in both target and non-target vessels. Moreover, adding CTA features to clinical models improved prediction of POCE (AUC, 0.71 to 0.76; P<0.01). CONCLUSION: Coronary CTA quantitative features were associated with residual cardiovascular events after complete revascularization at both patient and vessel levels and improved prognostic assessment beyond clinical factors.